Arrowhead Pharmaceuticals Inc (ARWR) Q3 2024 Earnings Call Highlights: Navigating Financial ...

GuruFocus News
4 min read

In This Article:

  • Net Loss: $170.8 million or $1.38 per share for the quarter ended June 30, 2024.

  • Revenue: No revenue recorded for the quarter ended June 30, 2024, compared to $15.8 million in the same quarter of 2023.

  • Operating Expenses: $176.1 million for the quarter ended June 30, 2024, up from $118.5 million in the same quarter of 2023.

  • Cash Used in Operating Activities: $115.4 million for the quarter ended June 30, 2024, compared to $21.4 million in the same quarter of 2023.

  • Cash and Investments: $436.7 million as of June 30, 2024.

  • Pro Forma Cash Balance: Approximately $840 million after the financing agreement with Sixth Street.

  • Common Shares Outstanding: 124.2 million as of June 30, 2024.

Release Date: August 08, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is advancing its 20 and 25 initiative, aiming to expand its pipeline to at least 20 clinical stage or marketed products by next year.

  • The company is making significant progress with plozasiran, its first wholly owned drug candidate, which has shown promising results in reducing triglycerides and is expected to launch next year if approved.

  • Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) has secured a $500 million senior secured credit facility from Sixth Street, providing long-term, low-cost, non-dilutive capital to support its pipeline and commercial launch efforts.

  • The company reported successful top-line results from the Phase 3 PALISADE study of plozasiran in patients with familial chylomicronemia syndrome (FCS), meeting its primary and all key secondary endpoints.

  • Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) is building a strong commercial infrastructure in preparation for the launch of plozasiran, with a focus on patient and caregiver support programs.

Negative Points

  • Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) reported a net loss of $170.8 million for the quarter ended June 30, 2024, compared to a net loss of $102.9 million in the same period last year.

  • The company recorded no revenue for the quarter ended June 30, 2024, compared to $15.8 million in the same quarter of the previous year.

  • Operating expenses increased significantly to $176.1 million for the quarter, driven by higher research and development costs as the company's pipeline advances.

  • Net cash used in operating activities was $115.4 million for the quarter, a substantial increase from $21.4 million in the same period last year.

  • There is uncertainty regarding the timing and outcome of regulatory approvals and the commercial launch of plozasiran, which could impact future revenue generation.

Recommended Stories